NASDAQ:XBIO - Xenetic Biosciences Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $2.42 0.00 (0.00 %) (As of 12/18/2018 10:17 AM ET)Previous Close$2.42Today's Range$2.42 - $2.4252-Week Range$1.37 - $8.95Volume337 shsAverage Volume61,830 shsMarket Capitalization$24.17 millionP/E RatioN/ADividend YieldN/ABeta1.61 ProfileDiscussionAnalyst RatingsChartEarningsInstitutional OwnershipHeadlinesSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Xenetic Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, research, and development of next-generation biologic drugs and novel orphan oncology therapeutics. The company's lead investigational product candidate is oncology therapeutic XBIO-101 (sodium cridanimod) for the treatment of progesterone resistant endometrial cancer. Its proprietary drug development platform, PolyXen, enables next-generation biologic drugs by improving their half-life and other pharmacological properties. The company has a research, development, license, and supply agreements with Shire plc, Serum Institute of India, PJSC Pharmsynthez, and SynBio LLC. Xenetic Biosciences, Inc. is headquartered in Lexington, Massachusetts. Receive XBIO News and Ratings via Email Sign-up to receive the latest news and ratings for XBIO and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:XBIO Previous Symbol CUSIPN/A Webwww.xeneticbio.com Phone781-778-7720 Debt Debt-to-Equity RatioN/A Current Ratio1.74 Quick Ratio1.74 Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$7.59 million Price / Sales3.00 Cash FlowN/A Price / Cash FlowN/A Book Value$1.64 per share Price / Book1.48 Profitability EPS (Most Recent Fiscal Year)N/A Net Income$-3,590,000.00 Net MarginsN/A Return on Equity-9.48% Return on Assets-6.99% Miscellaneous Employees5 Outstanding Shares9,400,000Market Cap$24.17 million OptionableNot Optionable Xenetic Biosciences (NASDAQ:XBIO) Frequently Asked Questions What is Xenetic Biosciences' stock symbol? Xenetic Biosciences trades on the NASDAQ under the ticker symbol "XBIO." How were Xenetic Biosciences' earnings last quarter? Xenetic Biosciences Inc (NASDAQ:XBIO) issued its quarterly earnings results on Wednesday, November, 15th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.23) by $0.03. The company had revenue of $0.09 million for the quarter. View Xenetic Biosciences' Earnings History. When is Xenetic Biosciences' next earnings date? Xenetic Biosciences is scheduled to release their next quarterly earnings announcement on Wednesday, December 19th 2018. View Earnings Estimates for Xenetic Biosciences. Has Xenetic Biosciences been receiving favorable news coverage? Headlines about XBIO stock have trended negative on Tuesday, according to InfoTrie Sentiment Analysis. InfoTrie ranks the sentiment of media coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Xenetic Biosciences earned a media sentiment score of -2.4 on InfoTrie's scale. They also gave headlines about the company a news buzz of 5.0 out of 10, indicating that recent media coverage is somewhat likely to have an effect on the company's share price in the next few days. Who are some of Xenetic Biosciences' key competitors? Some companies that are related to Xenetic Biosciences include Cumberland Pharmaceuticals (CPIX), Evofem Biosciences (EVFM), Scpharmaceuticals (SCPH), Avadel Pharmaceuticals (AVDL), Chiasma (CHMA), MOTIF BIO PLC/S (MTFB), Axsome Therapeutics (AXSM), Pharmaxis (PXSLY), Humanigen (HGEN), Entasis Therapeutics (ETTX), Tetraphase Pharmaceuticals (TTPH), Provention Bio (PRVB), Aridis Pharmaceuticals (ARDS), Mustang Bio (MBIO) and Immune Design (IMDZ). Who are Xenetic Biosciences' key executives? Xenetic Biosciences' management team includes the folowing people: Mr. Jeffrey F. Eisenberg, CEO, Pres & Director (Age 52)Mr. James F. Parslow, CFO, COO & Corp. Sec. (Age 53)Dr. Curtis A. Lockshin, Chief Scientific Officer (Age 58) Who are Xenetic Biosciences' major shareholders? Xenetic Biosciences' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc (0.38%) and Vanguard Group Inc. (0.38%). Which institutional investors are buying Xenetic Biosciences stock? XBIO stock was acquired by a variety of institutional investors in the last quarter, including Vanguard Group Inc and Vanguard Group Inc.. How do I buy shares of Xenetic Biosciences? Shares of XBIO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Xenetic Biosciences' stock price today? One share of XBIO stock can currently be purchased for approximately $2.42. How big of a company is Xenetic Biosciences? Xenetic Biosciences has a market capitalization of $24.17 million and generates $7.59 million in revenue each year. Xenetic Biosciences employs 5 workers across the globe. What is Xenetic Biosciences' official website? The official website for Xenetic Biosciences is http://www.xeneticbio.com. How can I contact Xenetic Biosciences? Xenetic Biosciences' mailing address is 99 HAYDEN AVENUE SUITE 230, LEXINGTON MA, 02421. The company can be reached via phone at 781-778-7720 or via email at [email protected]com. MarketBeat Community Rating for Xenetic Biosciences (NASDAQ XBIO)Community Ranking: 2.5 out of 5 ( )Outperform Votes: 83 (Vote Outperform)Underperform Votes: 82 (Vote Underperform)Total Votes: 165MarketBeat's community ratings are surveys of what our community members think about Xenetic Biosciences and other stocks. Vote "Outperform" if you believe XBIO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe XBIO will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 12/18/2018 by MarketBeat.com StaffFeatured Article: What is systematic risk?